b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="Publisher" Owner="NLM">\n        <PMID Version="1">32145097</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>03</Month>\n            <Day>24</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1472-8206</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <PubDate>\n                        <Year>2020</Year>\n                        <Month>Mar</Month>\n                        <Day>07</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Fundamental &amp; clinical pharmacology</Title>\n                <ISOAbbreviation>Fundam Clin Pharmacol</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Annexin A13 predicts poor prognosis for lung adenocarcinoma patients and accelerates the proliferation and migration of lung adenocarcinoma cells by modulating epithelial-mesenchymal transition.</ArticleTitle>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1111/fcp.12555</ELocationID>\n            <Abstract>\n                <AbstractText>This study aimed to investigate the role of ANXA13 in lung adenocarcinoma (LUAD) growth, migration, and the underlying mechanisms. Firstly, in the TCGA dataset for LUAD, ANXA13 is found to be highly expressed in patients with LUAD and high expression of ANXA13 predicted poor outcomes in LUAD patients. Consistently, the data of qRT-PCR showed that the expression of ANXA13 was higher in LUAD cell lines (Calu-3, LTEP-a-2, and NCI-H1395) than that in normal lung cell line BEAS2B. Then, we performed gain- and loss of function of ANXA13 in NCI-H1395 and Calu-3 cells, respectively. The results displayed that deficiency of ANXA13 suppresses cell proliferation, invasion, and migration in Calu-3 cells and overexpression of ANXA13 augments cell proliferation, invasion, and migration in NCI-H1395 cells. Finally, it was found that silencing of ANXA13 obviously raised the protein expression levels of E-cadherin and reduced the protein levels of N-cadherin, Vimentin, and Snail in Calu-3 cells whereas overexpression of ANXA13 obviously receded the protein expression levels of E-cadherin and enhanced the protein levels of N-cadherin, Vimentin, and Snail in NCI-H1395 cells. This study analyzed the biological effects of ANXA13 in LUAD cells, indicating that ANXA13 could regard as a therapeutic target for LUAD.</AbstractText>\n                <CopyrightInformation>\xc2\xa9 2020 Soci\xc3\xa9t\xc3\xa9 Fran\xc3\xa7aise de Pharmacologie et de Th\xc3\xa9rapeutique.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Xue</LastName>\n                    <ForeName>Guo-Liang</ForeName>\n                    <Initials>GL</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Oncology, The 960th Hospital of the PLA Joint Logistice Support Force, Jinan, 250031, Shandong, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhang</LastName>\n                    <ForeName>Cong</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiotherapy, The 960th Hospital of the PLA Joint Logistice Support Force, Jinan, 250031, Shandong, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zheng</LastName>\n                    <ForeName>Gui-Li</ForeName>\n                    <Initials>GL</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Oncology, The 960th Hospital of the PLA Joint Logistice Support Force, Jinan, 250031, Shandong, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhang</LastName>\n                    <ForeName>Lian-Jun</ForeName>\n                    <Initials>LJ</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Jinan Xunzheng Medicine Technology Development Center, Jinan, 250000, Shandong, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Bi</LastName>\n                    <ForeName>Jing-Wang</ForeName>\n                    <Initials>JW</Initials>\n                    <Identifier Source="ORCID">https://orcid.org/0000-0001-8319-7547</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Oncology, The 960th Hospital of the PLA Joint Logistice Support Force, Jinan, 250031, Shandong, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2020</Year>\n                <Month>03</Month>\n                <Day>07</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Fundam Clin Pharmacol</MedlineTA>\n            <NlmUniqueID>8710411</NlmUniqueID>\n            <ISSNLinking>0767-3981</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">annexin A13</Keyword>\n            <Keyword MajorTopicYN="N">epithelial-mesenchymal transition</Keyword>\n            <Keyword MajorTopicYN="N">lung adenocarcinoma</Keyword>\n            <Keyword MajorTopicYN="N">migration</Keyword>\n            <Keyword MajorTopicYN="N">proliferation</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>12</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2020</Year>\n                <Month>02</Month>\n                <Day>10</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2020</Year>\n                <Month>03</Month>\n                <Day>04</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2020</Year>\n                <Month>3</Month>\n                <Day>8</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>3</Month>\n                <Day>8</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2020</Year>\n                <Month>3</Month>\n                <Day>8</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>aheadofprint</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">32145097</ArticleId>\n            <ArticleId IdType="doi">10.1111/fcp.12555</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Title>References</Title>\n            <Reference>\n                <Citation>Yu C., Tian F., Liu J. et al. Circular RNA cMras inhibits lung adenocarcinoma progression via modulating miR-567/PTPRG regulatory pathway. Cell Prolif (2019) 52 e12610.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. (2018) 68 394-424.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Torre L.A., Siegel R.L., Jemal A. Lung cancer statistics. Adv. Exp. Med. Biol. (2016) 893 1-19.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Epsi N.J., Panja S., Pine S.R., Mitrofanova A. pathCHEMO, a generalizable computational framework uncovers molecular pathways of chemoresistance in lung adenocarcinoma. Commun. Biol. (2019) 2 334.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Yerukala Sathipati S., Ho S.Y. Identifying the miRNA signature associated with survival time in patients with lung adenocarcinoma using miRNA expression profiles. Sci. Rep. (2017) 7(1) 7507.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Yokota J., Kohno T. Molecular footprints of human lung cancer progression. Cancer Sci. (2004) 95 197-204.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Lizarbe M.A., Barrasa J.I., Olmo N., Gavilanes F., Turnay J. Annexin-phospholipid interactions. Functional implications. Int. J. Mol. Sci. (2013) 14 2652-83.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Gou R., Zhu L., Zheng M. et al. Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins. J. Transl. Med. (2019) 17 275.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Boye T.L., Jeppesen J.C., Maeda K. et al. Annexins induce curvature on free-edge membranes displaying distinct morphologies. Sci. Rep. (2018) 8 10309.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Grewal T., Enrich C., Rentero C., Buechler C. Annexins in adipose tissue: novel players in obesity. Int. J. Mol. Sci. (2019) 20 3449.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Jiang G., Wang P., Wang W., Li W., Dai L., Chen K..Annexin A13 promotes tumor cell invasion in vitro and is associated with metastasis in human colorectal cancer. Oncotarget (2017) 8 21663-21673.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>McCulloch K.M., Yamakawa I., Shifrin D.A. Jr et al. An alternative N-terminal fold of the intestine-specific annexin A13a induces dimerization and regulates membrane-binding. J. Biol. Chem. (2019) 294(10) 3454-3463.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Christensen M.V., H\xc3\xb8gdall C.K., Jochumsen K.M., H\xc3\xb8gdall E.V.S. Annexin A2 and cancer: A systematic review. Int. J. Oncol. (2018) 52 5-18.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Yao H., Sun C., Hu Z., Wang W. The role of annexin A4 in cancer. Front. Biosci. (2016) 21 949-57.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>K\xc3\xa4lsch J., Padden J., Bertram S. et al. Annexin A10 optimally differentiates between intrahepatic cholangiocarcinoma and hepatic metastases of pancreatic ductal adenocarcinoma: a comparative study of immunohistochemical markers and panels. Virchows Arch. (2017) 470 537-543.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>van Duin M., van Marion R., Vissers K.J. et al. High-resolution array comparative genomic hybridization of chromosome 8q: evaluation of putative progression markers for gastroesophageal junction adenocarcinomas. Cytogenet. Genome Res. (2007) 118 130-7.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Song J., Wang W., Wang Y. et al. Epithelial-mesenchymal transition markers screened in a cell-based model and validated in lung adenocarcinoma. BMC Cancer (2019) 19 680.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Gerke V., Creutz C.E., Moss S.E. Annexins: linking Ca2+ signalling to membrane dynamics. Nat. Rev. Mol. Cell Biol. (2005) 6 449-61.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Biaoxue R., Xiguang C., Hua L., Tian F., Wenlong G..Increased level of annexin A1 in bronchoalveolar lavage fluid as a potential diagnostic indicator for lung cancer. Int. J. Biol. Markers (2017) 32 e132-e140.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Boudhraa Z., Bouchon B., Viallard C., D\'Incan M., Degoul F. Annexin A1 localization and its relevance to cancer. Clin Sci (2016) 130 205-20.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Feng X., Liu H., Zhang Z., Gu Y., Qiu H., He Z. Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells. J. Exp. Clin. Cancer Res. (2017) 36 123.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Reiske H., Sui B., Ung-Medoff H. et al. Identification of annexin A13 as a regulator of chemotherapy resistance using random homozygous gene perturbation. Anal. Quant. Cytol. Histol. (2010) 32 61-9.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Joseph J.P., Harishankar M.K., Pillai A.A., Devi A..Hypoxia induced EMT: A review on the mechanism of tumor progression and metastasis in OSCC. Oral Oncol. (2018) 80 23-32.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Tang Y., Xuan Y., Qiao G. et al. MDM2 promotes epithelial-mesenchymal transition through activation of Smad2/3 signaling pathway in lung adenocarcinoma. Onco. Targets Ther. (2019) 12 2247-2258.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Yuan L., Zhou M., Huang D. et al. Resveratrol inhibits the invasion and metastasis of colon cancer through reversal of epithelial mesenchymal transition via the AKT/GSK3beta/Snail signaling pathway. Mol. Med. Rep. (2019) 20 2783-2795.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>De Craene B., Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer (2013) 13 97-110.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Niu M., Ma F., Qian J. et al. Ncadherin attenuates nucleus pulposus cell senescence under highmagnitude compression. Mol. Med. Rep. (2018) 17 2879-2884.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Richardson A.M., Havel L.S., Koyen A.E. et al. Vimentin Is required for lung adenocarcinoma metastasis via heterotypic tumor cell-cancer-associated fibroblast interactions during collective invasion. Clin. Cancer Res. (2018) 24 420-432.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Scheel C., Weinberg R.A. Cancer stem cells and epithelial-mesenchymal transition: Concepts and molecular links. Semin. Cancer Biol. (2012) 22 396-403.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Tsoukalas N. et al.Epithelial-mesenchymal transition in non small-cell lung cancer. Anticancer Res. (2017) 37 1773-1778.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Ma Q., Lu Y., Lin J., Gu Y. ENKUR acts as a tumor suppressor in lung adenocarcinoma cells through PI3K/Akt and MAPK/ERK signaling pathways. J. Cancer (2019) 10 3975-3984.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Yan X., Chang J., Sun R. et al. DHX9 inhibits epithelial-mesenchymal transition in human lung adenocarcinoma cells by regulating STAT3. Am. J. Transl. Res. (2019) 11 4881-4894.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Sun R., Liu Z., Qiu B. et al. Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway. EBioMedicine (2019) 47 142-155.</Citation>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'